Pharmacutical Apixaban Market Set for Rapid Growth And Trend by | Page 2

REPORT DESCRIPTION
Apixaban Market : Overview
Increasing prevalence of venous thromboembolism related conditions is expected to
aid in growth of the apixaban market. For instance, according to International
Society on Thrombosis and Haemostasis 2014 facts, revealed that around 10 million
cases of venous thromboembolism occur annually across low, middle and high
income countries. Moreover, increasing therapeutic indications for apixaban is
expected to boost the apixaban market growth. For instance, in 2014, the U.S. Food
and Drug Administration approved Eliquis for the treatment of deep vein
thrombosis (DVT) prophylaxis and pulmonary embolism (PE) and also for the
reduction in risk of recurrent PE and DVT following initial therapy. Furthermore,
government and private organizations are significantly investing capital in
healthcare research and development and this is also likely to propel growth of the
Apixaban market. However, adverse effects of apixaban such as increased risk of
thrombotic events after premature discontinuation and bleeding is expected to
hamper adoption of this. This in turn is expected to adversely affect growth of the
market. According to a study published in the Current Medical Research and
Opinion 2017 stated about the bleeding risk associated with use of apixaban.
© Coherent market Insights. All Rights Reserved